CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages

Table 5

SN, SP, PPV, and NPV of CA125, HE4, ROMA, and CPH-I in differentiating BOT I+II from EOC I+II group stratification by pathology.

Menopausal status	SN (%)	SP (%)	PPV (%)	NPV (%)
Serous
HE4	76.74	90.11	78.57	89.13
CA125	60.47	75.82	54.17	80.23
ROMA	79.07	86.81	73.91	89.77
CPH-I	83.72	74.73	61.00	90.70
Mucinous
HE4	70.00	85.00	53.85	91.89
CA125	70.00	72.50	38.89	90.63
ROMA	70.00	80.00	53.33	91.43
CPH-I	90.00	67.50	40.90	96.40
Endometrioid
HE4	39.13	100	100	39.13
CA125	52.17	77.78	85.71	38.89
ROMA	43.48	100	100	40.91
CPH-I	65.22	77.78	88.20	46.70

Abbreviations: SN = sensitivity; SP = specificity; PPV = positive predictive value; NPV = negative predictive value; BOT I+II = borderline ovarian tumors in FIGO stages I and II; EOC I+II = epithelial ovarian cancer in FIGO stages I and II.